WellPoint draws ire for pushing generics: Pfizer asks docs to resist cheaper statins
Indianapolis-based WellPoint Inc. is in a tussle with the nation’s largest drug maker over the nation’s top-selling drug. New York-based Pfizer Inc., facing the loss of billions in sales of its Lipitor cholesterol-fighting drug, sent letters last month to doctors, encouraging them to protest the attempts of health benefits firms to switch patients to generic cholesterol drugs. The letter, which says the change is being pushed “for cost reasons alone,” reached doctors several days after Well-Point expanded a promotion to…